Compare

Septerna, Inc. vs Protagonist Therapeutics, Inc vs Cumberland Pharmaceuticals Inc vs Integrated Biopharma Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearSepterna, Inc.
SEPN
Protagonist Therapeutics, Inc
PTGX
Cumberland Pharmaceuticals Inc
CPIX
Integrated Biopharma Inc
INBP
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenue$45.95M$46.02M$44.52M$43.87M
Revenue growth (YoY)n/m-89.4%+17.6%-19.3%
Gross marginn/an/a85.0% (computed)1.8%
Operating margin-148.6%-343.6%-6.3%-6.2%
Net margin-106.4%-282.8%-6.4%-6.5%
Net income-$48.88M-$130.15M-$2.84M-$2.84M
EPS (Diluted)-$1.10-$2.05-$0.19-$0.09
Operating cash flow$110.19M$57.67M$4.93M$1.24M
Free cash flow$109.67M$56.08M$4.83M$895.0K
Cash & equivalents$120.72M$128.39M$11.44M$4.47M
Total assets$596.19M$668.19M$76.82M$25.34M
Total liabilities$214.26M$53.48M$52.28M$7.67M
Shareholders' equity$381.93M$614.71M$24.88M$17.67M
Return on year-end equity-12.8%-21.2%-11.4%-16.1%
Shares outstanding44.81M62.58M14.96M31.06M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearSepterna, Inc.Protagonist Therapeutics, IncCumberland Pharmaceuticals IncIntegrated Biopharma Inc
Latest$45.95M
Ended 2025-12-31
$46.02M
Ended 2025-12-31
$44.52M
Ended 2025-12-31
$43.87M
Ended 2026-06-30
1 year earlier$1.07M
Ended 2024-12-31
$434.43M
Ended 2024-12-31
$37.87M
Ended 2024-12-31
$54.35M
Ended 2025-06-30
2 years earlier$151.0K
Ended 2023-12-31
$60.00M
Ended 2023-12-31
$39.55M
Ended 2023-12-31
$50.32M
Ended 2024-06-30
3 years earliern/a$26.58M
Ended 2022-12-31
$42.01M
Ended 2022-12-31
$50.67M
Ended 2023-06-30
4 years earliern/a$27.36M
Ended 2021-12-31
$35.05M
Ended 2021-12-31
$56.25M
Ended 2022-06-30